文献速递骨软组织肉瘤与黑色素瘤

评估无复发生存作为黑色素瘤辅助免疫检查点抑制剂治疗总生存替代终点的潜力

Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2020-08-07

该研究基于EORTC 18071伊匹木单抗试验的个体患者数据及其他辅助试验已发表结果,采用荟萃分析框架评估RFS作为OS替代终点。中位随访5.3年时,患者水平RFS与OS强相关(ρ=0.84),试验水平中等相关(R2=0.59)。将EORTC 18071加入回归分析后,既往干扰素试验中观察到的试验水平关联似乎得以维持,但需更多辅助试验数据确认。

要点

  • 患者水平RFS与OS强相关(ρ=0.84,95%CI 0.82-0.87)。
  • 试验水平RFS与OS中等相关(R2=0.59,95%CI 0.08-1.00)。
  • 干扰素试验中试验水平关联在加入EORTC 18071后似乎维持。

核心结论

  • 在黑色素瘤辅助免疫检查点抑制剂治疗中,RFS与OS在患者水平强相关,在试验水平中等相关。
  • 既往干扰素试验中观察到的试验水平关联在加入EORTC 18071结果后似乎得以维持。
  • 需更多辅助试验数据确认RFS作为OS替代终点的关联强度。

研究设计与样本

  • 采用荟萃分析框架,使用EORTC 18071伊匹木单抗试验的个体患者数据及其他辅助试验的已发表结果。

主要发现

  • 中位随访5.3年时,患者水平RFS与OS强相关(ρ=0.84;95%CI 0.82-0.87)。
  • 试验水平RFS与OS中等相关(R2=0.59;95%CI 0.08-1.00)。

局限性

  • 需更多辅助试验数据确认RFS与OS在试验水平关联的强度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Recent changes in the adjuvant treatment of melanoma have raised interest in confirming relapse-free survival (RFS) as a surrogate for overall survival (OS). METHODS: We explore this issue with the meta-analytic framework, using individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab and published results from other adjuvant trials. RESULTS: The individual patient data analysis results at a median follow-up of 5.3 years showed a strong association between RFS and OS at the patient level (ρ = 0.84; 95% confidence interval [CI]: 0.82-0.87) and a moderate association at the trial level (R2 = 0.59; 95% CI: 0.08-1.00). CONCLUSIONS: The trial-level association previously observed in interferon-based trials appeared to be maintained when the EORTC 18071 results were added to a regression analysis using published results from other trials. More data from adjuvant trials are required to confirm the strength of association between RFS and OS in this setting.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Coart E, Suciu S, Squifflet P, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. Eur J Cancer. 2020. PMID: 32777716. doi:10.1016/j.ejca.2020.07.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。